clinical trials disclosure services
Thousands of Records Posted, >90% without NIH Comments


Clinical Trials Disclosure
Finding experienced resources to register and report your clinical trial, provide document redaction services, or locating the right team for end-to-end management and support of an entire portfolio of studies can be difficult.
Our Clinical Trials Disclosure (CTD) experts are here for you.
Our dedicated team of disclosure experts have successfully maintained thousands of studies across multiple registries/therapeutic areas and redacted thousands of pages to meet a myriad of transparency obligations (including EU Clinical Trial Regulation (CTR)/Clinical Trial Information System (CTIS), Policy 0070, and Health Canada Public Release of Clinical Information (PRCI)).
All Clinical Trials Disclosure Services
Let our seasoned project managers and authors navigate you through the ever-evolving clinical trials disclosure landscape and build a custom solution to achieve your clinical trials disclosure and transparency objectives.

Clinical Trials Disclosure Services
Document Redaction/Anonymization
ProPharma provides resources, guidance, and support for both anonymization and document redaction.
Document Redaction
ProPharma’s redaction specialists leverage a proprietary redaction software platform to review, assess, and redact thousands of pages of documents subject to data anonymization and transparency initiatives through the application of both industry standards (e.g., TransCelerate) and agency- and client-specific guidelines across the following types of requests:
- Regulatory agencies
- European Medicines Agency (EMA) Policy 0043 (EU Access to Documents), Policy 0070, and EU Clinical Trial Regulation (CTR) (via Clinical Trial Information System (CTIS))
- U.S Food and Drug Administration (FDA) FDAAA Section 801 and Final Rule
- Health Canada Public Release of Clinical Information (PRCI)
- The scientific community: journal publication requests
- The broader public: third party requests to satisfy internal company transparency initiatives
ProPharma can also provide QC review of documents that are already redacted, to ensure all required information has been appropriately redacted consistently across all documents.
Our experienced redaction specialists can manage internal review and approval processes of marked for redaction documents to deliver a final, marked for redaction version of all applicable documents

In support of EU CTIS submissions, ProPharma has direct experience providing the following redaction services and support:
- Redaction of all core (EU wide) and supporting documents, as well as country- and site-specific documents (national) needed for submission (Part I and Part II)
- Redaction of amended documents following Member State Requests for Information (RFIs)
- Redaction of site-specific, native-language documents
- Rapid response teams to ensure RFI response timelines are met within all required turnaround times
In support of EMA Policy 0070 and Health Canada PRCI redactions, ProPharma provides the following comprehensive redaction services and support:
- Development of redaction strategy/report
- SME consultation to prepare for health authority interactions
- Application of color-specific overlays for personal data and commercially confidential information (CCI) in compliance with either European Medicines Agency (EMA) or Health Canada requirements
- Development of CCI and personally protected information (PPI) checklists
- Performance of online searches for potential CCI in the public domain
- Internal reviews to ensure consistency across documents
- Completion of justification table for CCI
- Preparation and/or review of anonymization report
Anonymization
ProPharma has expert knowledge in both policies and the public release that guide anonymization and provides retrospective AND prospective anonymization services to anonymize data to acceptable, quantifiable levels without sacrificing data utility. With constant and clear communication and collaboration, ProPharma provides the following anonymization services:
- Development of an anonymization plan
- Quantitative risk assessment
- Multiple application options: randomization, generalization, masking
- Robust QC procedures for all programming
- Internal testing to maintain utility and determine risk of re-identification
- Development of final anonymization report
- Quick dataset turnaround time without sacrificing quality
Clinical Trial Registry Authoring
ProPharma provides resources and expert guidance in support of compliant clinical trial registry authoring across multiple global (including country-specific) registries.
Clinical trial registry authoring at ProPharma includes:
- Initial protocol registration (protocol summary registration): initial review to determine what studies need to be registered, to which registry(ies), and within what specific timeframe
- Ongoing registry maintenance (monthly/annual updates): track and manage each registry deliverable through the use of a customized client dashboard to ensure all applicable updates are completed and compliance is maintained
- Clinical trials results: determination of in-scope vs. out-of-scope, timing of relevant results entry (i.e., final vs. interim reporting), and filing of certification of delay
Multiple independent, documented QC reviews are performed throughout the lifecycle of each deliverable, ensuring an accurate, high-quality, and compliant record is produced. All timelines and processes are adaptable and customizable to accommodate business needs.
Our vast clinical trial registry authoring experience includes but is not limited to the following individual registries:
- ClinicalTrials.gov
- EudraCT/EU CTIS
- JapicCTI/jRCT
- European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP)
- EU Post-Authorization Studies (PAS) Register
- Individual country registries (e.g., CTRI, DRKS/BfArM)
- Client-specific registries

Key features of ProPharma's success in the clinical trial registry authoring space include:
- ProPharma clinical trials disclosure authors are experts at distilling the scientific data from the source documents into the necessary form to meet all registry requirements.
- ProPharma's registry authoring process is fully managed and supported internally
- ProPharma's clinical trials disclosure authors drive the process, engaging stakeholder teams at pivotal times throughout
- ProPharma's clinical trials disclosure authors are adept and seasoned project managers who effectively manage each project from start to finish
- ProPharma can use client SOPs and processes/procedures, but has also developed internal SOPs and processes as well as the internal infrastructure and governance, which can be implemented to augment and support existing client procedures and fully operationalize the ProPharma team or leveraged to function completely independently
- ProPharma proactively identifies trends in evolving changes in individual registry requirements and implements them to avoid future comments
Plain Language Authoring
ProPharma's experienced plain language team of experts works with clients to develop relevant and timely, non-promotional plain language documents including but not limited to:
- Informed consent forms
- Plain language protocol synopses (in compliance with EU CTR)
- Plain language summaries (EU CTR, UK, etc.)
ProPharma's solutions-focused team of plain language experts also help clients develop the foundational documents and processes designed to ensure the success of their plain language program. These include (but are not limited to):

- Plain language templates: customized to individual client requirements, graphics and color scheme options, providing standardized text for information and awareness fields
- Quality review checklists
- Customized patient questionnaires (to be used during patient review/user testing to collect feedback designed to improve readability of each plain language document)
- Implementation and execution of patient reviews/user tests
- Plain language libraries: promotes efficiency in producing future plain language documents and can help with translational memory (TM) to reduce future costs
ProPharma's value proposition lies in the following formula for success in providing plain language authoring services:
- Skilled plain-language authors with direct plain language experience encompassing multiple therapy areas, including but not limited to oncology, cardiovascular, endocrinology, nephrology, CNS, ophthalmology, and inflammation
- Autonomously drive the document development process
- Active participation in the plain language community to maintain health literacy knowledge and training through regular attendance at relevant disclosure conferences, workshops, etc.
- Talented and experienced graphic artists to design and create custom graphics to facilitate visually aesthetic comprehension
- Experienced engineers of patient review panels/user testing, assimilating feedback downstream to produce reader-friendly materials
- Skilled architects in the design and implementation of portfolio-specific lay language libraries that provide a framework for future growth and maintenance
- Leverage industry partnerships to provide certified, country-specific translation of plain language documents into approximately 40 different languages
Management Consultation
ProPharma provides management consultation services in which we leverage our subject matter expertise and guidance to help you understand, interpret, and apply relevant legislation and regulations. Services include but are not limited to:
- Regulatory guidance
- Stakeholder education/training
- Disclosure audit/gap analysis
- Client process development and documentation
ProPharma’s clinical trials disclosure SMEs work with clients to help determine what studies need to post, by when and to which registries, as well as what additional documentation (if any) may be needed to complete the registrations. We also provide guidance as to which studies may be eligible for extensions in reporting (i.e., Certification of Delay on Clinicaltrials.gov), assisting with the requests, as needed.

In addition, our expertise can be leveraged to conduct a gap analysis to identify any potential deviations in compliance, providing what support is needed to bring each study into full compliance.
We also offer comprehensive stakeholder education and training, which can be implemented in a single department or across an entire client organization as needed to develop and/or implement disclosure policies and processes. We work with clients to develop individual training plans based on their business needs.
ProPharma remains embedded and actively involved in the clinical trials disclosure community, so that we can remain abreast of changes, incorporating them into our processes and informing our clients as needed. Our SMEs regularly attend conferences and workshops and are active members in organizations such as Drug Information Association (DIA), volunteering and participating in multiple ad hoc CTD working groups (e.g., EU CTIS working group, Policy 0070 working group, Country Registry Working Group, Final Rule Working Group, Avoiding PRS Comments Working Group, etc.).
Contact Us See our Clinical Trials Disclosure FAQsQuestions About Clinical Trials Disclosure?
Clinical Trials Disclosure Frequently Asked Questions
How are you successful in the clinical trials disclosure space?
High quality of our deliverables
Through the use of a documented and systematic approach that builds quality into the document as it evolves through the lifecycle, >90% of records authored by ProPharma are made public with no regulatory review (NIH) comments, which is much higher than our competitors and has the added benefit of reducing the overall cost of the record.

What is your clinical trials disclosure registry workflow?
We have mapped out an integrated process, with all documentation, governance, and infrastructure needed to enable immediate startup of any disclosure project.
The use of detailed step-by-step process maps, guidance documents, document templates, and other job aids ensures consistency, quality, and adherence to applicable regulations.
We work with each client to tailor and individualize the process and all accompanying documentation to accommodate any additional client specifications.

IDENTIFY & REPORT
- Review materials to identify applicable reportable information
- Prepare compliant registry record

ENGAGE
- Early engagement of study team
- Solicit and incorporate study team input, confirming alignment with study details

REVIEW
- Multiple internal reviews for both content and quality
- Subject matter expert reviews to ensure compliance with applicable registry guidelines

FINALIZE
- Obtain final approval
- Upload to registry
Additional Clinical Trials Disclosure Frequently Asked Questions
Click on frequently asked questions about ProPharma's clinical trials disclosures to learn about our experience and expertise.
We specialize in providing clinical trials disclosure services including redaction services to pharmaceutical/biotech companies of all sizes (including small, mid-size, and big pharma).
ProPharma recognizes that the recent increase in legislation broadening the scope of required transparency can be a challenge to navigate as you work to stay compliant while balancing your commercial obligations.
In response, to this ProPharma developed a management consultation program as a complement to our clinical trial registry authoring and redaction services. Through this program, we provide expert consultation and guidance to help with understanding, interpreting, and applying the relevant regulations to individual programs and studies.
In addition, we remain active participants in the clinical trials disclosure community, attending and participating in industry conferences, volunteering for working groups, attending workshops and seminars, and collaborating with industry partners to stay abreast of evolving trends. Whenever possible, we share that knowledge with our clients to ensure compliance and improve efficiency.
In our vast experience, the overall process for developing a protocol registration or authoring a results posting can be highly variable and dependent on multiple factors. For that reason, our process timeline is flexible and can be modified to accommodate individual client needs such as study priority, team bandwidth, or other company needs, including compression of timelines to meet imminent compliance deadlines.
As an example, provided all materials needed to produce a complaint posting are available, a protocol registration can be completed in approximately 17-20 business days, and a results posting can be completed in 25-30 business days. Both of these estimates assume a single round (5 business days) of client review.
The critical success factors in writing a plain language summary include but are not limited to:
- Early identification of number of countries and specific languages required for translation
- Utilizing an experienced plain language medical writer AND a developed, well-structured template
- Ability to leverage the ICF language (a well-written ICF can save time for plain language summary development)
- Early alignment with the appropriate key stakeholders on which outcomes will be presented (e.g., primary and safety only, or primary and key secondary and safety)
- Thoughtful application of readability measures/tools
- Judicious, complementary use of graphics that contribute to the overall readability and comprehension of the document
- Leveraging timelines to produce a shell document early, completing with data once tables, listings, and graphs are available
- Agreeing upon (and adhering to) a strategic timeline for stakeholder review
- Having a strong project manager assigned to keep the project on track and ensure milestone integrity
- Understanding the target audience: incorporation of a structured and well-designed patient review (user test) of the plain language summary to capture end user feedback
- Actively implementing and incorporating feedback received from the patient review/user testing
- Having a proactive and engaged study team who understands (to some degree) the plain language summary requirements
- Setting the expectation that a Master English version will be fully approved by the team before any translations
- If translations are required, involving the linguist(s) early on in the project
- Wherever possible, centralizing translations
ProPharma uses an innovative technology platform that leverages AI and automation to identify and redact or de-identify both PPI (Personally Protected Information) and CCI. Our experienced redaction specialists apply a methodical two-step approach to the redaction of each document, to ensure patient and company confidential information are appropriately identified.
Once all content has been identified for redaction, each document undergoes a rigorous quality review to ensure not only the protection of all relevant information but also the consistent application of all applicable standards and regulations (including both industry standards (e.g., TransCelerate) and client-specific guidelines).
Our innovative redaction technology platform:
- Provides data and document de-identification and anonymization
- Can redact multiple documents at once
- Allows for multiple input types (.xpt, .sas, .pdf, etc)
- Determines risk for re-identification and data utility
- Auto-generates anonymization reports
- Allows for re-use by applying the appropriate formatting based on intended audience without the need to re-redact/re-review
Yes. ProPharma's redaction subject matter experts (SMEs) work with clients to develop internal ‘rule sets’ or parameters for the redaction of CCI. We can help guide which functions should be involved in identifying and reviewing for CCI, conduct searches in the public domain to ensure the information labeled as CCI has not already been disclosed, and build a living document that can be deployed across portfolios to increase efficiency.
Throughout the process, ProPharma leverages multiple guidance documents, regulatory drivers, and previous experience including (but not limited to):
- TransCelerate and/or PhUSE de-identification standards
- Country-specific guidance (e.g., EMA document-specific guidance)
- Internal company policies/guidelines
- Previous health authority feedback and interactions
Yes. ProPharma’s redaction SMEs provide comprehensive health authority interaction support, which includes but is not limited to:
- Facilitation of meeting setup and delivery
- Facilitation of EMA review of justification tables
- Consultation and support of RFIs
- Work with EMA for CCI review and finalization to avoid rework
Yes! ProPharma can redact site-specific documents in English as well as multiple native EU languages (e.g., German, Italian, French, Dutch, Spanish, etc).
"I am delighted to share this amazing news with you. Results of all 5 clinical studies have been released to ClinicalTrials.gov. An important milestone has been achieved!!! The project was challenging in so many aspects – pressing timelines, high complexity of the studies, multiple competing priorities, and I would like to take the moment to thank ProPharma Group and Kateric team for your hard work, determination, and dedication. It was a pleasure and a privilege working with such fantastic professionals!"
"I am delighted to share this amazing news with you. Results of all 5 clinical studies have been released to ClinicalTrials.gov. An important milestone has been achieved!!! The project was challenging in so many aspects – pressing timelines, high complexity of the studies, multiple competing priorities, and I would like to take the moment to thank ProPharma Group and Kateric team for your hard work, determination, and dedication. It was a pleasure and a privilege working with such fantastic professionals!"
Our Typical Clinical Trials Disclosure Clients Are Those That Need:

INTERNAL DISCLOSURES DEPARTMENT
Clients with limited internal clinical trials disclosure resources who need to outsource all clinical trials disclosure activities

AUTHOR SUPPORT
Clients who need to outsource individual clinical trials disclosure components as an augment to existing internal clinical trials disclosure resources

SHORT-TERM AD-HOC SUPPORT
Clients who need to outsource individual clinical trials disclosure components in support of an individual project
News & Insights

September 27, 2023
The Impact of a US Government Shutdown on the Food and Drug Administration
U.S. lawmakers are actively attempting to negotiate a deal to prevent a government shutdown on October 1, 2023. Along with many other government agencies, the ability of the Food and Drug...

September 25, 2023
DSCSA Requirements and Responsibilities for Drug Manufacturers (Sponsor vs CMO)
With the final deadline for complete compliance with the FDA's Drug Supply Chain Security Act (DSCSA) looming on the horizon, where do you find your organization? Although the FDA has now issued two...

September 27, 2023
ProPharma Appoints Alena Hammond as Global Head of Clinical Operations
Raleigh, NC, September 27, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

September 13, 2023
ProPharma Introduces ClinCHAT, a Solution to Unleash the Power of Real-World Evidence with Conversational AI
Raleigh, NC, September 13, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

August 30, 2023
ProPharma Expands Regulatory Sciences Team in the Japan and Asia-Pacific Region with Addition of Neama Baho
RALEIGH, NC, August 30, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

May 3, 2022
ProPharma Group Named Top 10 CRO 2022 by Pharma Tech Outlook
ProPharma Group Named Top 10 CRO 2022 by Pharma Tech Outlook A Customer-Centric Approach to Clinical Research Solutions ProPharma Group is honored to be named Top 10 CRO 2022 by Pharma Tech Outlook...

April 21, 2022
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards: ProPharma Group is honored to be awarded “Best Pharmaceutical Regulatory & Compliance...

June 10, 2022
The Cost of Poor Project Management
Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

August 31, 2022
Successfully Passing MHRA Inspections for Overseas Manufacturing Sites
ProPharma Group offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma Group’s Compliance and Quality team completed the...
News & Insights

September 27, 2023
ProPharma Appoints Alena Hammond as Global Head of Clinical Operations
Raleigh, NC, September 27, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

September 13, 2023
ProPharma Introduces ClinCHAT, a Solution to Unleash the Power of Real-World Evidence with Conversational AI
Raleigh, NC, September 13, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

August 30, 2023
ProPharma Expands Regulatory Sciences Team in the Japan and Asia-Pacific Region with Addition of Neama Baho
RALEIGH, NC, August 30, 2023: ProPharma Group (ProPharma), the leading global provider of regulatory, clinical and compliance services for the life sciences industry, and a portfolio company of...

April 21, 2022
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards
ProPharma Group Named Best Pharmaceutical Regulatory & Compliance Consultancy: 2022 Corporate Excellence Awards: ProPharma Group is honored to be awarded “Best Pharmaceutical Regulatory & Compliance...

Sep 27, 2023 11:57:42 AM
The Impact of a US Government Shutdown on the Food and Drug Administration
U.S. lawmakers are actively attempting to negotiate a deal to prevent a government shutdown on October 1, 2023. Along with many other government agencies, the ability of the Food and Drug...

Sep 25, 2023 4:59:00 PM
DSCSA Requirements and Responsibilities for Drug Manufacturers (Sponsor vs CMO)
With the final deadline for complete compliance with the FDA's Drug Supply Chain Security Act (DSCSA) looming on the horizon, where do you find your organization? Although the FDA has now issued two...

October 14, 2021
Accelerate European Market Access with Compliant and Comprehensive MAA Submission
Preparedness for Marketing Authorization Application (MAA) approval ensures an efficient application process and follow-up. Placing a medicinal product in the European market requires a license for...

March 18, 2022
Outsourcing QA - Reduce Time and Expense While Meeting Critical Requirements
There is a tendency for VPCs to rely solely on the QC/QA units within their outsourced CMO to perform quality functions. However, the sponsor organization has the ultimate responsibility for product...

October 14, 2021
Dedicated Project Manager Directs Regulatory Activities Throughout European Economic Area
Learn how a single point of contact oversaw local regulatory affairs activities across all 31 countries of the EEA. You’re developing a drug, biologic, or medical device product. There are a lot of...

September 1, 2022
Webinar: AI-Powered MI Contact Centers: Key Considerations for a Scalable & Global Medical Information Capability
Today's Medical Information (MI) industry is being driven by evolving customer behavior requiring a more rapid, omnichannel, and digital response to customer needs. The expectation for higher...

October 14, 2021
Ensure Successful Acquisitions with Complete and Accurate Regulatory Due Diligence
Ensure you have as much information as possible to thoroughly evaluate the potential investment when acquiring a company or product. When considering the acquisition of a new company or product, it...

October 14, 2021
Ensure Successful Batch Release, Regulatory Compliance with Experienced Qualified Persons
Streamlining a CMO’s manufacturing process helped ensure GMP compliance for EU batch release and USA inspection readiness. A contract manufacturing organization (CMO) needs to have a reliable quality...

September 28, 2023
How a Two-Part NDA Regulatory Strategy Resulted in Submission Success
Developing a New Drug Application (NDA) for submission to the FDA is an extremely complex process and one that can present challenges to even the most seasoned professionals. From ensuring you have...

October 4, 2021
How to Minimize Overdue Deviations: A Multi-Site Process Improvement Approach
A global biopharmaceutical client with multiple sites operating under a Warning Letter from the U.S. Food and Drug Administration (FDA) needed significant cross-functional support to meet remediation...

October 14, 2021
Identify At-Risk Drug Products and Ensure Compliance Before Nitrosamines Deadline
Risk evaluation of products containing chemically synthesized APIs must be done to assess adherence to nitrosamine regulations. Marketing Authorization Holders (MAHs) must perform a risk evaluation...

October 4, 2021
Increased Visibility for Senior Management with Custom PMO Design, Implementation
Time. Regardless of company size and the number of products in your portfolio, time is one thing we could all use more of. However, the more projects you have in your portfolio, the more stretched...

October 14, 2021
Initiating Enrollment for Accelerated COVID-19 Treatment Studies in 6 Days
In May 2020, as the FDA released new guidelines to accelerate the development of novel COVID-19 therapeutics and vaccines, our Clinical Services experts were asked to provide independent Data Safety...

October 14, 2021
MICC Overflow Solution Was Successfully Deployed and Preserved Customer Satisfaction
A routine safety letter to healthcare professionals (HCPs) was misinterpreted by recipients, causing a “recall-like” crisis event for a multinational pharmaceutical client. When a routine safety...

September 28, 2023
Insider Talks - The Journey of ATMPs From the Discovery to Routine GMP Real Life
In the competitive and fast-moving Cell and Gene Therapy (CGT) field, developers face a range of scientific, technical, and regulatory challenges that can quickly become overwhelming and costly. In...

May 19, 2022
Insider Talks - Tips to Adapt to Today’s Auditing Environment, an Auditor’s Perspective
As businesses face the shared global challenges of adapting to new operating models triggered by the recent pandemic, regulated drug and device sponsors, marketing authorization holders, and...

March 25, 2022
Insider Talks - To Decentralize or Not to Decentralize … That is the Question
Having a decentralized approach is critical to ensuring continuity in the face of disaster, and important in meeting your overall enrollment goals while increasing patient diversity. Join us for our...

October 14, 2021
Secure Timely Product Launch by Ensuring GDP Compliance Across Europe
Our client was in the phase of submitting a Marketing Authorization Application (MAA) in the EU and needed to apply for a Wholesale Distribution Authorization (WDA). After application and approval of...

October 14, 2021
Transfer and Manage Clinical Data Provided by Multiple Third-Party Vendors
Managing and sharing large amounts of clinical data provided by a team of ten plus vendors is extremely challenging and requires meticulous attention to detail and expert-level project management to...

October 14, 2021
Understanding Clinical Trial Requirements for Medical Device Label Extensions
After you have developed an FDA-regulated product and obtained marketing approval, you may think your job is done. However, after all the time, effort, money, and so much more that goes into product...

September 28, 2023
What You Need to Know About Regulatory Programs for Expedited Approval
Differentiating between the FDA and EMA's expedited approval pathways can be tricky. Learn the similarities and differences between them to help determine the best option(s) for your product. The...

October 17, 2021
Outsourcing of Medical Information Content Creation: Experience of 100 Clients
The time and effort required to write, review, edit, approve, maintain, distribute, and update Medical Information (MI) documents while retaining an auditable record of the search strategy is a great...

October 4, 2021
Outsourcing Medical Information Services: When to Consider a Dedicated Resource
Outsourcing Medical Information (MI) services can be an effective solution for ensuring the provision of MI services to HCPs and consumers globally. The most cost-effective model for the provision of...

May 3, 2023
Improve Quality & Consistency by Leveraging AI for Trial Master File Classification
Improve Quality and Consistency by Leveraging AI for Trial Master File Classification The whitepaper "Improve Quality and Consistency by Leveraging AI for Trial Master File Classification" addresses...